ArticleNature communications2022

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.

Wu-Tong Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.